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     AMLA ENHANCES AUTOPHAGY AND MODULATES BETA AMYLOID METABOLISM IN AN  
    IN VITRO MODEL OF ALZHEIMER’S DISEASE 
 
 
 
Figure1B: The western blotting results aretransformed with 
Quantity One software The immunoblotting Quantity One 
software has  confirmed the visualization of bands. (* p<0.05, ** 
p<0.01). 
Beta-amyloid (Aβ) deposition in the brain as extracellular plaques is 
a neuropathological hallmark of Alzheimer disease (AD)(2). The 
accumulation and aggregation of beta amyloid (Aβ), resulting from 
its over-production or impaired clearance from the CNS plays a key 
role in the Alzheimer disease pathogenesis (1).   
Reducing production, preventing Aβ aggregation or improving its 
clearance are currently some areas of active research in the 
development of therapeutic agents to ameliorate neurodegeneration 
in AD. The Indian plant amla (Emblica officinalis), commonly known 
as Indian gooseberry, has widely been utilized in traditional 
Ayurvedic medicine preparations in the treatment of a variety of 
disease conditions including cardiovascular disease, diabetes. 
Accumulating evidence also suggests that amla may be beneficial in 
AD (3).  Recent evidence reports increased autophagy following 
amla treatment. (4). Amla has shown enhanced the expression of the 
autophagic proteins LC3B-II and beclin1 in an in vitro significantly 
(4).  Autophagy is a vital mechanism involved in the clearance of 
aggregated proteins and damaged organelles in cells. Enhancing 
autophagy has shown to reduce amyloid deposition and 
neurodegeneration in AD models and is a potential therapeutic 
strategy for AD and several neurodegenerative disorders (5). The 
main aim of this study is to investigate the effects of amla on 
modulation of autophagy and beta amyloid metabolism underlying.  
Human embryonic kidney 293 APP cells are transfected with human 
APP bearing the Swedish mutation (HEK293 APPsw). HEK293 
APPswe cell line was kindly provided from Prof Paul Fraser 
laboratory.  
The purified, standardized dried extract of amla which is known as 
Amlamax is used for treating the cells.  
3mg of amla powder was dissolved in 10 liters 37 °C DMEM 
medium and vortex several times. 
HEK293 cells expressing APPswe line were treated with amla (50-
300ug/ml) for 24 hours.  
Expression level of Full length APP, APP C-terminal fragment and 
marker of autophagy LC3 in HEK293 APPswe cells were measured in 
cell lysates following amla treatment. 
The primary antibodies used in this project are summarised in Table1.   
 
 
  
INTRODUCTION 
Preliminary data shows that amla treatment enhances autophagy and 
modulates accumulation of proteolytic products of Amyloid precursor 
protein (APP) such as APP-C terminal fragments (C99).  
•Amla treatment (50-300 μg/ml) induced a dose-dependent increase in 
autophagic flux, as measured by Western blotting utilizing an LC3 
directed antibody as an autophagosome marker.  
 
•At similar concentrations, amla treatment also reduced accumulation of 
APP C-terminal fragment levels by 33 to 77%. 
 
• no significant changes were observed in APP levels, indicating that 
amla did not alter APP production. 
 
•One of the valuable component of amla which has shown significant 
effect in inducing autophagy via increasing the expression of autophagic 
proteins is quercetin (4).  
Future : 
• To determine if amla mediated autophagy contributes to enhanced 
clearance/degradation of Aβ in neuronal cells. 
• To determine if amla reduce Aβ aggregation and toxicity. 
•Investigate the effect of amla on Aβ42 oligomerization and toxicity 
Overall, our findings suggest that amla may confer beneficial effects 
through modulating autophagy and Aβ metabolism, and warrants further 
investigation as a potential therapeutic agent in AD. 
SUMMARY 
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Figure 1 A. Expression of FL-APP (A1), APP-CTF(C99) (A2), marker of 
autophagy LC3 (A3) and GAPDH levels of APP in treated HEK2 93swe 
cells (50-300 μg/ml) are (triplicate) similar (A1) levels of increasing 
concentration  of amla(50-300 μg/ml) significant reduced C.terminal 
fragment in a  in HEK293swe (triplicate) (A2) and significant increased 
levels of LCE biomarker (A3).  
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           Antibodies  WB Host 
Primary 
Anti-Amyloidβ Antibody (WO2) (M) 1:3000 
Mouse 
Primary 
Anti-APP CTF (C99) (C1/1.6) IgG (M) 1:1000 
Mouse 
Primary 
Anti-LC3 (p.m03.6)  1:2500 
Rabbit 
Primary 
Anti-Glyceraldehyde-3phosphatedehydrogenase (GAPDH) (M) 
 
5:000 
Rabbit 
Experience of proteins of interest in treated HEK 293APPswe cell  
line with amla 
 
(M) denotes monoclonal antibody  
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